ID   HepAD43
AC   CVCL_DE22
SY   Hep AD43
DR   cancercelllines; CVCL_DE22
DR   Wikidata; Q54882830
RX   PubMed=21331898;
CC   Population: Caucasian.
CC   Biotechnology: Control cell line for the bioassay based on HepAD38 (Cellosaurus=CVCL_M177) or HepAD79 (Cellosaurus=CVCL_DE23).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: UniProtKB; P00722; Escherichia coli lacZ.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 16
//
RX   PubMed=21331898; DOI=10.1385/1-59259-245-7:43;
RA   King R.W., Ladner S.K.;
RT   "Hep AD38 assay: a high-throughput, cell-based screen for the
RT   evaluation of compounds against hepatitis B virus.";
RL   Methods Mol. Med. 24:43-50(2000).
//